55154-30-8 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

55154-30-8 Usage

Description

AH 7921 (Item No. 12036) is an analytical reference material categorized as an opioid. It is an analgesic with high addictive liability in animal models. AH 7921 is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

Check Digit Verification of cas no

The CAS Registry Mumber 55154-30-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,1,5 and 4 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 55154-30:
(7*5)+(6*5)+(5*1)+(4*5)+(3*4)+(2*3)+(1*0)=108
108 % 10 = 8
So 55154-30-8 is a valid CAS Registry Number.

InChI:InChI=1/C16H22Cl2N2O/c1-20(2)16(8-4-3-5-9-16)11-19-15(21)12-6-7-13(17)14(18)10-12/h6-7,10H,3-5,8-9,11H2,1-2H3,(H,19,21)

55154-30-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name	3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide

1.2 Other means of identification

Product number	-
Other names	AH-7921

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55154-30-8 SDS

55154-30-8Upstream product

55154-30-8Downstream Products

55154-30-8Relevant articles and documents

Pharmacological Characterization of Low-to-Moderate Affinity Opioid Receptor Agonists and Brain Imaging with 18F-Labeled Derivatives in Rats

Ott, Julian,Spilhaug, Mona M.,Maschauer, Simone,Rafique, Waqas,Jakobsson, Jimmy E.,Hartvig, Karoline,Hübner, Harald,Gmeiner, Peter,Prante, Olaf,Riss, Patrick J.

, p. 9484 - 9499 (2020)

The 3,4-dichloro-N-(1-(dimethylamino)cyclohexyl)methyl benzamide scaffold was studied as a template for 18F-positron emission tomography (18F-PET) radiotracer development emphasizing sensitivity to changes in opioid receptor (OR) occupancy over high affinity. Agonist potency, binding affinity, and relevant pharmacological parameters of 15 candidates were investigated. Two promising compounds 3b and 3e with μ-OR (MOR) selective agonist activity in the moderate range (EC50 = 1-100 nM) were subjected to 18F-fluorination, autoradiography, and small-animal PET imaging. Radioligands [18F]3b and [18F]3e were obtained in activity yields of 21 ± 5 and 23 ± 4% and molar activities of 25-40 and 200-300 GBq/μmol, respectively. Displaceable binding matching MOR distribution in the brain was confirmed by imaging. Radioligands showed a rapid pharmacokinetic profile; however, metabolite-corrected, blood-based modeling was required for data analysis. Observed BPND was low, although treatment with naloxone leads to a marked decrease in specific binding, confirming the discovery of a new template for 18F-labeled OR-agonist PET ligands.

AH-7921 DETECTION

-

Paragraph 0072; 0073, (2016/09/26)

Antibodies, immunoassay methods and kits for the detection and determination of 3,4,-dichloro-N-[(1-(dimethylamino)cyclohexyl)methyl]benzamide and 3,4,-dichloro-N-[(1-(methylamino)cyclohexyl)methyl]benzamide, as well as the precursory immunogens, are described.

CAS

55154-30-8